Connect with us
DAPA Banner
DAPA Coin
DAPA
COIN PAYMENT ASSET
PRIVACY · BLOCKDAG · HOMOMORPHIC ENCRYPTION · RUST
ElGamal Encrypted MINE DAPA
🚫 GENESIS SOLD OUT
DAPAPAY COMING

Business

Novo Nordisk sues Eli Lilly over weight-loss drug comparison ads

Published

on

Novo Nordisk sues Eli Lilly over weight-loss drug comparison ads

Novo Nordisk sued Eli Lilly on Tuesday, accusing its rival of misleading consumers by claiming Lilly’s drugs work better than Novo’s competing treatments.

The lawsuit, filed in federal court in New Jersey, argues that Lilly’s ads for Zepbound and Mounjaro compared the highest doses of its drugs with lower doses of Novo’s Wegovy and Ozempic. Novo said the ads rely on “outdated” trial data, according to Reuters.

Advertisement

“The ads are maliciously and deceptively false because Lilly knowingly cites outdated clinical trials that compare the highest doses of the Lilly medicines to lower doses of Novo Nordisk’s medicines,” Novo said in its complaint.

TOM BRADY TEAMS WITH DIGITAL HEALTH FIRM EMED TO EXPAND GLP-1 WEIGHT LOSS MEDICATION ACCESS

A photo illustration of Ozempic pen

A photo illustration shows an Ozempic injection pen in London on June 17, 2026. The lawsuit argues that Lilly’s ads for Zepbound and Mounjaro compared the highest doses of its drugs with lower doses of Novo’s Wegovy and Ozempic.  (Peter Dazeley/Getty Images / Getty Images)

Meanwhile, Lilly rejected the claims and said its ads are based on its SURMOUNT-5 trial, completed in 2024, which compared patients taking 10 mg or 15 mg of Zepbound with those taking 1.7 mg or 2.4 mg of Wegovy.

The FDA approved a higher 7.2 mg dose of Wegovy in March, Reuters reported.

Advertisement

“The gold standard for comparing medicines is a robustly designed, well-conducted head-to-head clinical trial — like SURMOUNT-5, which remains the only head-to-head, randomized clinical trial directly comparing tirzepatide and semaglutide in weight management,” a Lilly spokesperson told FOX Business in an email.

AMERICANS PAYING LESS AS TRUMP DRUG PRICING PUSH SLASHES GLP-1, FERTILITY MEDICINE COSTS, OFFICIAL SAYS

photo illustration of Zepbound with instruction sheet on a white background. It is an injectable medication used for chronic weight management

A photo illustration shows a Zepbound injection pen and instruction sheet on a white background. Lilly rejected the claims and said its ads are based on its SURMOUNT-5 trial, completed in 2024. (Michael Siluk/UCG/Universal Images Group via Getty Images / Getty Images)

“Rather than compete on the merits of its products, Novo is asking a court to stop Lilly from communicating the results of that trial. We stand firmly behind our advertising,” the spokesperson added. “It is truthful, it is transparent, and it is grounded in the most direct scientific evidence available — exactly what patients deserve. We will continue to focus on the science and defend against this lawsuit vigorously.”

Novo is asking the court to order Lilly to remove the ads and run corrective advertising. It is also seeking damages tied to any profits Lilly may have earned from the campaign.

Advertisement

The two companies are competing for control of the fast-growing obesity drug market in the U.S., which analysts say could be worth more than $100 billion by the end of the decade, according to Reuters.

TARGET BEEFS UP PROTEIN, SUPPLEMENT OFFERINGS, CAPITALIZING ON WEIGHT LOSS DRUG TREND

photo illustration of weight loss injection pens on a weight scale showing 176 pounds

A photo illustration shows weight-loss injection pens resting on a scale that reads 176.8 pounds. The two companies are competing for control of the fast-growing obesity drug market in the U.S. (Michael Siluk/UCG/Universal Images Group via Getty Images / Getty Images)

Novo said it sent Lilly a cease-and-desist letter in April but received no response.

GET FOX BUSINESS ON THE GO BY CLICKING HERE

Advertisement

The company also said Lilly’s revised ads have been shown more than 700 million times since late April.

Novo Nordisk could not immediately be reached by FOX Business for comment.

Reuters contributed to this report.

Advertisement
Continue Reading
Click to comment

You must be logged in to post a comment Login

Leave a Reply

Business

Oil prices to hit $120 soon? Goldman Sachs makes big prediction as Hormuz concerns loom

Published

on

Oil prices to hit $120 soon? Goldman Sachs makes big prediction as Hormuz concerns loom
Wall Street major Goldman Sachs has warned that Brent crude could surge to $120 per barrel if disruptions through the Strait of Hormuz, the world’s most critical oil transit route, persist, even as its base case assumes an eventual easing of tensions in the Middle East.

Goldman Sachs expects Brent crude to average $80 per barrel in the fourth quarter and $75 next year, assuming tensions in the Middle East ease. However, the risks to its forecasts remain “tilted to the upside” due to potential disruptions to shipping through the Strait of Hormuz and possibly the Red Sea, analysts said.

Global energy markets have faced renewed volatility this month, with Brent climbing back above $91 per barrel amid fresh fighting between the U.S. and Iran and a threat by Iran-backed Houthi rebels in Yemen to blockade shipments from Saudi Arabia. Red Sea routes have played a key role in enabling Persian Gulf crude cargoes affected by disruptions to reach buyers.

Also read: Relieved that crude has finally fallen? The real warning signs just began flashing elsewhere

Advertisement

Goldman Sachs said lower global inventories in the second quarter have increased the oil market’s vulnerability to supply shocks. However, weaker Chinese imports and greater demand elasticity could limit the potential for further price gains.

Crude oil price today

Oil prices edged lower on Tuesday as markets weighed reports of renewed diplomatic efforts between the U.S. and Iran, including a proposed 10-day ceasefire, against continued military exchanges and a threat by Yemen’s Houthis to impose a naval blockade on Saudi Arabia.
A senior Iranian official told Reuters that Tehran had received a 10-day ceasefire proposal from mediators. The initiative aims to preserve the interim agreement signed on June 17 and create a path toward a lasting deal to end the conflict that began on February 28 following U.S.-Israeli attacks on Iran.
The diplomatic push followed another night of U.S. strikes on Iranian cities and retaliatory attacks by Iran’s Revolutionary Guards on U.S. military assets across the region. U.S. Central Command later said on Monday that it had launched another round of strikes on Iran.
The U.S. carried out its 10th consecutive day of strikes after President Donald Trump vowed that Iran “will pay” for the killing of American soldiers. Iran responded with attacks on Kuwait.

The conflict began on February 28, when the U.S. and Israel launched attacks on Iran. Tehran retaliated with strikes on Israel and Gulf states that host U.S. military bases. U.S.-Israeli attacks on Iran, along with Israeli strikes on Lebanon during the conflict, have killed thousands of people and displaced millions.

Also read:Oil is crude once again! Is $95 the new normal and what it means for Indian investors?

Advertisement

Over the past week, Trump has also threatened to widen the scope of U.S. strikes in Iran to include energy facilities and bridges.

The 1949 Geneva Conventions, which set rules for humanitarian conduct during war, prohibit attacks on sites considered essential to civilian life. Following Trump’s earlier threats to target such infrastructure, international law experts in the U.S. said earlier this year that such attacks could potentially constitute war crimes.

(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of The Economic Times)

Advertisement
Continue Reading

Business

Interactive Brokers Group, Inc. (IBKR) Q2 2026 Earnings Call Transcript

Published

on

OneWater Marine Inc. (ONEW) Q1 2026 Earnings Call Transcript